Drug intelligence / Profile preview

EVO-005

Development stage: Preclinical
Lead developer: Evozyne
Modality: Recombinant Proteins and Enzymes
Administration: Parenteral

Overview

EVO-005 is a preclinical-stage therapeutic candidate being developed by Evozyne for the treatment of autoimmune diseases. The drug is a novel protein engineered using Evozyne's proprietary generative AI platform, which simulates protein evolution to design optimized functional proteins with enhanced properties. As of 2026, the specific molecular target and modality (e.g., enzyme, cytokine, or antibody-like protein) remain undisclosed, though the program is part of Evozyne's internal pipeline focused on addressing dysregulated immune responses.

Targets

IgG (Immunoglobulin G)

Beyond the preview

Go deeper on EVO-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EVO-005.

Explore the full profile